Menus Subscribe Search

Follow us


Breast Cancer Court Case Pits Patients’ Genes vs. Gene Patents

• April 07, 2011 • 11:23 AM

A court case surrounding gene patents for high-risk forms of breast cancer puts two viewpoints of “products of nature” on the stand.

The United States Court of Appeals for the Federal Circuit heard a case earlier this week involving a fine point of patent law with major implications for public health and science: Can individual human genes be patented by private companies?

The United States Patent and Trademark Office has, in fact, been saying yes for years. According to one 2005 study published by the journal Science, gene patents for 20 percent of the human genome — or more than 4,000 genes — have been created, despite court precedent that says no one can own the “products of nature.”

This particular case, brought by the American Civil Liberties Union and the Public Patent Foundation on behalf of several cancer patients and scientific organizations, revolves around a pair of genes associated with an elevated risk of breast and cervical cancer. The genes BRCA1 and BRCA2 have been patented by the private firm Myriad Genetics, making it the only company that can test and diagnose women for the mutation (at a cost of a few thousand dollars).

“Everybody that we’ve talked to — and we’ve all talked to doctors and told them about this case — everybody’s shocked to know that this DNA is patented,” said Sabrina Hassan, senior counsel for Public Patent.

Last March, a federal court in New York agreed that genes shouldn’t be patented. And then in the fall, the federal government surprisingly filed a friend-of-the-court brief agreeing with the cancer patients and the district judge in Myriad’s appeal. Neal Katyal, the U.S. acting solicitor general, argued in court alongside the ACLU’s lawyers on Monday, effectively opposing the government’s own longstanding policy on the question.

[class name="dont_print_this"]

Idea Lobby

THE IDEA LOBBY
Miller-McCune's Washington correspondent Emily Badger follows the ideas informing, explaining and influencing government, from the local think tank circuit to academic research that shapes D.C. policy from afar.

[/class] That move looks like a “change of heart” on the government’s part, said Aaron Kesselheim, an assistant professor of medicine at Harvard Medical School. He and colleague Michelle Mello wrote about the case in the New England Journal of Medicine last May, tracking a historical context in U.S. gene patent policy that now appears to be shifting.

“It is significant,” Kesselheim said, “that the government has come out on the plaintiffs’ side on this case and said this probably is not what the Patent Act was meant to cover.”

While the human genome is obviously a product of nature, the patent office has long approved applications by companies for the work of isolating individual genes. Myriad holds patents both on the isolated BRCA1 and BRCA2 and on the process it uses to compare those genes when diagnosing women for the risk.

The lawsuit rests largely on the question of whether merely isolating something in nature should make it patentable — and the court’s ultimate answer would affect not just these two genes but the notion that any DNA is patentable.

“If a surgeon cuts me open and slices out my kidney and takes it out and holds it in his hand, it’s an ‘isolated’ kidney, but it’s still a kidney,” argued ACLU lawyer Chris Hansen in court on Monday. “It’s not an invention.”

The ACLU has also argued that patenting the process of comparing DNA, as Myriad does in its diagnostic tests, is akin to patenting thought.

Myriad counters that gene patents are essential to luring the investment money needed to conduct the research that isolates such DNA in the first place, allowing for the development of advances in personal medicine that benefit society as a whole.

Both parties are, in a sense, arguing that their positions benefit patients. And this touches on the other big question raised by the case: Does society stand to gain more when patents encourage financial investment in scientific innovation or when public ownership of genes spurs wider research and cheaper diagnostic tools?

Kesselheim pointed to one recent study that has tried to answer this question. Economist Heidi Williams compared gene sequencing by the public Human Genome Project with the private firm Celera to determine whether intellectual property rights really spurred innovation. She found that assigning intellectual property to genes sequenced by Celera led to less future research and product development than did the public effort.

If the appeals court upholds the earlier decision in the BRCA case — a substantial break in policy for gene patenting, Kesselheim said, but a narrow one that would not extend to other naturally occurring substances like proteins — Kesselheim predicts society won’t lose out on important basic research. After all, much of the work in this area (including research that led to the genes Myriad ultimately patented) is supported by the government.

But this is a separate policy issue.

“The government is funding this initial research, and on the other hand, patients are paying extremely high costs for the output of the research,” Kesselheim said. “That means patients are paying twice — once in their taxes and once out of their pocket — for the same output.”

Sign up for the free Miller-McCune.com e-newsletter.

“Like” Miller-McCune on Facebook.

Follow Miller-McCune on Twitter.

Add Miller-McCune.com news to your site.

Subscribe to Miller-McCune

Emily Badger
Emily Badger is a freelance writer living in the Washington, D.C. area who has contributed to The New York Times, International Herald Tribune and The Christian Science Monitor. She previously covered college sports for the Orlando Sentinel and lived and reported in France.

More From Emily Badger

A weekly roundup of the best of Pacific Standard and PSmag.com, delivered straight to your inbox.

Recent Posts


September 30 • 10:09 AM

Trust Is Waning, and Inequality May Be to Blame

Trust in others and confidence in institutions is declining, while economic inequality creeps up, a new study shows.


September 30 • 8:00 AM

The Psychology of Penmanship

Graphology: It’s all (probably) bunk.



September 30 • 6:00 AM

The Medium Is the Message, 50 Years Later

Five decades on, what can Marshall McLuhan’s Understanding Media tell us about today?


September 30 • 4:00 AM

Grad School’s Mental Health Problem

Navigating the emotional stress of doctoral programs in a down market.


September 29 • 1:21 PM

Conference Call: Free Will Conference


September 29 • 12:00 PM

How Copyright Law Protects Art From Criticism

A case for allowing the copyright on Gone With the Wind to expire.


September 29 • 10:00 AM

Should We Be Told Who Funds Political Attack Ads?

On the value of campaign finance disclosure.


September 29 • 8:00 AM

Searching for a Man Named Penis

A quest to track down a real Penis proves difficult.


September 29 • 6:00 AM

Why Do So Many People Watch HGTV?

The same reason so many people watch NCIS or Law and Order: It’s all a procedural.


September 29 • 4:00 AM

The Link Between Depression and Terrorism

A new study from the United Kingdom finds a connection between depression and radicalization.


September 26 • 4:00 PM

Fast Track to a Spill?

Oil pipeline projects across America are speeding forward without environmental review.


September 26 • 2:00 PM

Why Liberals Love the Disease Theory of Addiction, by a Liberal Who Hates It

The disease model is convenient to liberals because it spares them having to say negative things about poor communities. But this conception of addiction harms the very people we wish to help.


September 26 • 1:21 PM

Race, Trust, and Split-Second Judgments


September 26 • 9:47 AM

Dopamine Might Be Behind Impulsive Behavior

A monkey study suggests the brain chemical makes what’s new and different more attractive.


September 26 • 8:00 AM

A Letter Becomes a Book Becomes a Play

Sarah Ruhl’s Dear Elizabeth: A Play in Letters From Elizabeth Bishop to Robert Lowell and Back Again takes 900 pages of correspondence between the two poets and turns them into an on-stage performance.


September 26 • 7:00 AM

Sonic Hedgehog, DICER, and the Problem With Naming Genes

Wait, why is there a Pokemon gene?


September 26 • 6:00 AM

Sounds Like the Blues

At a music-licensing firm, any situation can become nostalgic, romantic, or adventurous, given the right background sounds.


September 26 • 5:00 AM

The Dark Side of Empathy

New research finds the much-lauded feeling of identification with another person’s emotions can lead to unwarranted aggressive behavior.



September 25 • 4:00 PM

Forging a New Path: Working to Build the Perfect Wildlife Corridor

When it comes to designing wildlife corridors, our most brilliant analytical minds are still no match for Mother Nature. But we’re getting there.


September 25 • 2:00 PM

Fashion as a Inescapable Institution

Like it or not, fashion is an institution because we can no longer feasibly make our own clothes.


September 25 • 12:00 PM

The Fake Birth Mothers Who Bilk Couples Out of Their Cash by Promising Future Babies

Another group that’s especially vulnerable to scams and fraud is that made up of those who are desperate to adopt a child.


September 25 • 10:03 AM

The Way We QuickType


Follow us


Trust Is Waning, and Inequality May Be to Blame

Trust in others and confidence in institutions is declining, while economic inequality creeps up, a new study shows.

Dopamine Might Be Behind Impulsive Behavior

A monkey study suggests the brain chemical makes what's new and different more attractive.

School Counselors Do More Than You’d Think

Adding just one counselor to a school has an enormous impact on discipline and test scores, according to a new study.

How a Second Language Trains Your Brain for Math

Second languages strengthen the brain's executive control circuits, with benefits beyond words.

Would You Rather Go Blind or Lose Your Mind?

Americans consistently fear blindness, but how they compare it to other ailments varies across racial lines.

The Big One

One company, Amazon, controls 67 percent of the e-book market in the United States—down from 90 percent five years ago. September/October 2014 new-big-one-5

Copyright © 2014 by Pacific Standard and The Miller-McCune Center for Research, Media, and Public Policy. All Rights Reserved.